Related Experiment Video
Updated: Aug 3, 2026
Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes
Published on: May 31, 2018
Assessment of dendritic cell number and radiosensitivity in laryngeal tumours
P Nix1, N Stafford, L Cawkwell
1Division of Cell and Molecular Medicine, Postgraduate Medical Institute, University of Hull in Association with Hull York Medical School, University of Hull, Hull, UK.
Objectives:
Radiotherapy is one of the principal treatment modalities for many types of head and neck tumour; what effects the dendritic cell (DC) population may have on treatment outcome have not been critically evaluated in laryngeal cancer.
Design:
Retrospective, case-controlled study using immunohistochemistry to investigate the presence of S-100 positive DC in pre-treatment, archival biopsy tissue of early stage laryngeal cancers.
Setting:
Patients with laryngeal cancer treated with radiotherapy in Head and Neck Departments in England.
Participants:
Patients diagnosed with early stage laryngeal cancer, treated with single modality radiotherapy with curative intent. Radioresistant tumours (n = 22), defined as recurrent tumours within 12 months of therapy. Radiosensitive tumours (n = 22), defined as no recurrence with a minimum follow-up of 36 months.
Main Outcome Measures:
Density of S-100 staining DC on three x200 magnified microscopic fields.
Results:
DC were present in approximately equal numbers in both radioresistant and radiosensitive laryngeal tumour pre-treatment biopsies and therefore density did not correlate with radiotherapy treatment outcome (P = 0.420).
Conclusion:
There is no intrinsic deficiency in DC number in radioresistant laryngeal tumours meaning that such tumours could potentially benefit from vaccination strategies that enhance the specific anti-tumour immune response.
